Codexis, Inc. (NASDAQ:CDXS) Q4 2025 Earnings Call Transcript March 11, 2026 Codexis, Inc. beats earnings expectations. Reported EPS is $0.1056, expectations were $-0.03. Operator: Greetings. Welcome ...

An important study has uncovered an unexpected molecular player that helps make cancer cells stress-resilient, thereby promoting the survival, growth and progression of tumours. Researchers have ...

"Follow the water" has been a guiding mantra of astrobiology, and even space exploration more generally, for decades. If you ...

Researchers discovered that a small region of the PRC2 protein complex acts as a functional switch controlling gene silencing. Removing this domain stopped cancer cell growth, highlighting a potential ...

Non-intoxicating cannabinoids, cannabidiol (CBD) and cannabigerol (CBG), have shown promise in treating fatty liver disease in preclinical models. The corresponding study was published in the British ...

Earnings call Codexis reported Q4 2025 revenue of $38.9M (up 81% YoY), with full-year revenue rising 19% to $70.4M. Product gross margin improved to 64% (from 56% prior year). 2026 revenue is guided ...

Good afternoon, everyone, and thank you for standing by, and welcome to the Corvus Pharmaceuticals Fourth Quarter and Full Year 2025 Business Update and Financial Results Conference Call. [Operator ...

Researchers at NYU Langone Health have detected tiny plastic fragments in nine out of 10 prostate cancer tumors examined, a ...

For five decades, scientists have known about a notorious cancer-causing enzyme called SRC. But they always assumed it only ...

Making a living brain transparent and watching its neurons fire without disturbing their function—sounds like science fiction, doesn't it? Yet the solution may already exist within our own bodies. In ...

This study presents valuable findings that could potentially allow a deeper understanding of the immunopathogenesis underlying influenza infection in aged mice. The results are based on solid evidence ...